Investing

Cramer: Promising data from coronavirus drug trial ‘beginning of the end of the true nightmare’

Jim Cramer

Scott Mlyn | CNBC

CNBC’s Jim Cramer said Wednesday that positive news from Gilead Sciences about a potential treatment for the coronavirus marked a turning point in the fight against Covid-19.

“What I regard this as is the beginning of the end of the true nightmare, which is that it’s a death sentence,” Cramer said on “Squawk Box.”

U.S. stocks soared on Wednesday after Gilead indicated it was seeing positive, preliminary signs about the effectiveness of its antiviral remdesivir in treating coronavirus patients.

Cramer has been hopeful about remdesivir as a possible treatment.

Last week, the “Mad Money” host said, he believes that scientists testing treatments for the coronavirus will succeed in getting patients “out of the hospital faster” and reducing “death sentence” concerns.

On Thursday, Cramer said at the time, “I do feel better about what Gilead is doing.”

Products You May Like

Articles You May Like

The Once ‘Best’ Medigap Plan F Is No Longer The Best
Escaping The Sunk Cost Trap: How Behavioral Economics Can Improve Your Daily Decisions
What borrowers need to know as the Public Service Loan Forgiveness program goes on a partial processing pause
‘A lot of money on the sidelines’: Calamos Investments thinks ETFs should target CD, money market customers
Here’s what’s driving Friday’s stock action in Apple, Coterra and Eli Lilly

Leave a Reply

Your email address will not be published. Required fields are marked *